# Concord Biotech (CONCORDBIO) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/concordbio

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹628
- Change: -6.64%
- As of: 2026-11-06
- 1D return: -6.64%
- 5D return: +0.83%
- 1M return: -5.62%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

CONCORDBIO is in a confirmed bearish trend on daily and monthly timeframes, with the price at ₹628.00 trading below all major moving averages and the Supertrend indicator. The setup is characterized by high volatility (annualized ~45%) and significant downside momentum, evidenced by an extreme downward gap on 2026-11-04 (-46.6% return) and a subsequent weekly gap down on 2026-11-06. While the weekly Supertrend remains bullish, the daily ADX of 22.45 indicates developing but active selling pressure, contrasting with the strong monthly trend (ADX 46.4). The stock is positioned near the middle of its 20-day and 252-day ranges but at the lower end of its 50-day range. Immediate resistance lies at ₹628.62, while support is found at ₹626.47. A break below ₹626.47 would likely extend losses toward ₹606.25. Conversely, a sustained move above ₹640.23 would be required to challenge the immediate downtrend structure.

- Trend: Daily and monthly trends are bearish (price below Supertrend and MAs); weekly trend shows mixed signals with price below MAs but above Supertrend.
- Momentum: Extreme negative returns observed recently, including a -46.6% drop on 2026-11-04 and a -6.6% weekly gap down on 2026-11-06.
- Levels: Immediate resistance at ₹628.62; key support levels at ₹626.47 (near-term) and ₹606.25 (intermediate).
- Risk: High volatility environment with annualized volatility of +45.4% and current drawdown of -46.5%; ADX suggests developing daily trend strength.

- Bullish Engulfing Reversal
- Evening Star

### News Context

Concord Biotech is undergoing a significant corporate restructuring through a 1:1 bonus share issue, with November 4, 2026, designated as the record date. The company approved the issuance of 10.46 crore bonus shares (face value ₹1 each) by capitalizing its share premium account, with allotments scheduled for November 5. This action doubles the number of outstanding shares while proportionally adjusting the share price, leaving total investment value unchanged. On November 4, the stock appeared to fall nearly 50% due to trading platforms displaying unadjusted previous closing prices rather than the post-bonus valuation, creating a technical distortion rather than a fundamental loss.

The timing of this corporate action coincides with a period of price weakness; the stock has declined approximately 13% in 2026 and over 15% in the past month. The bonus issue was announced in September, with November 3 serving as the final cutoff for investors to hold shares in demat accounts to qualify for the allotment. While the late Rakesh Jhunjhunwala’s associates remain holders, media reports highlight the bonus as a key event for smallcap pharma investors this week, though no new operational or financial performance data was released during this seven-day window.

- Corporate Action: Concord Biotech issued a 1:1 bonus share ratio, creating 10.46 crore new shares from share premium capitalization, with allotment on November 5, 2026.
- Record Date Mechanics: November 4, 2026, is the record date; investors must hold shares by November 3 to qualify, triggering a proportional price adjustment that caused apparent 50% trading drops on some platforms due to unadjusted historical pricing displays.
- Price Context: The bonus announcement follows a decline of ~13% in 2026 and 15% over the preceding month, with no accompanying earnings or operational updates reported in this window.
- Ownership Note: Media coverage identifies the company as backed by the late Rakesh Jhunjhunwala, with his associates maintaining holdings, though specific transaction details are not provided.

- [Multibagger Jhunjhunwala stock is showing 50% fall today; here's why](https://www.businesstoday.in/markets/stocks/story/multibagger-jhunjhunwala-stock-is-showing-50-fall-today-heres-why-565560-2026-11-04)
- [Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanza](https://economictimes.indiatimes.com/markets/stocks/news/bonus-issue-alert-last-day-to-buy-this-rakesh-jhunjhunwala-backed-smallcap-pharma-stock-for-11-bonus-bonanza/articleshow/135479214.cms)
- [Dividend, bonus issue: Last chance to buy today — Godrej Consumer, Coal India, Asian Paints and others](https://www.livemint.com/market/stock-market-news/dividend-bonus-issue-last-chance-to-buy-today-godrej-consumer-coal-india-asian-paints-and-others-11793640245000.html)
- [Bonus share: Just single issue with record date this week: Pharma firm's free shares with 68% returns since IPO; ratio](https://www.livemint.com/market/stock-market-news/bonus-share-just-single-issue-with-record-date-this-week-pharma-firms-free-shares-with-68-returns-since-ipo-ratio-11793517001201.html)

### What Changed

Concord Biotech (NSE: CONCORDBIO) has materially altered its capital structure through a bonus share issue, while the stock price has retreated from recent levels. On November 5, 2026, the company intimated the allotment of 10,46,16,204 fully paid-up bonus equity shares to eligible shareholders, executed in a 1:1 ratio based on the record date of November 4, 2026. This corporate action, approved via Board circular resolution, has doubled the company's paid-up share capital to Rs. 20,92,32,408/-, divided into an equivalent number of equity shares of Rs. 1/- each.

Market pricing reflects a shift in valuation dynamics following this event. As of the observation date of November 6, 2026, the share price stood at ₹628.00, down from a previous recorded level of ₹671.00. The bonus issuance increases the total number of outstanding shares without changing the underlying business assets or operations, which typically adjusts the per-share market value proportionally. Investors should note that the immediate post-allotment price movement indicates how the market is currently re-pricing the equity relative to the expanded share count.

- Corporate Action: Allotment of 10,46,16,204 bonus shares (1:1 ratio) completed on November 5, 2026, doubling paid-up capital to Rs. 20,92,32,408/-.
- Price Movement: Share price declined to ₹628.00 as of November 6, 2026, compared to the previous reference price of ₹671.00.
- Capital Structure: Total equity shares outstanding now stand at 20,92,32,408, with a face value of Rs. 1/- per share.

- [Intimation of allotment of Bonus equity shares |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CONCORD_05112026180857_Concord_Intimation_of_Allotment.pdf)

### Official Filings

Concord Biotech Limited has completed the allotment of 10,46,16,204 bonus equity shares following a 1:1 ratio approved by the Board. The record date for this corporate action was November 04, 2026, and the intimation to the exchange was filed on November 05, 2026. This allotment increases the company's paid-up share capital to Rs. 20,92,32,408, divided into an equal number of equity shares with a face value of Rs. 1/- each.

In parallel, the company disclosed the transcript of its Q2 and H1 FY27 earnings call held on October 28, 2026. Management reported that Q2 revenue reached Rs. 309.1 crore, representing a 25% year-on-year increase, while H1 revenue stood at Rs. 566.6 crore, up 26%. These filings confirm the execution of the bonus issue and provide recent operational performance metrics.

- Bonus Issue Completed: Allotment of 10,46,16,204 fully paid-up bonus shares executed in a 1:1 ratio based on the November 04, 2026 record date.
- Capital Structure Update: Paid-up share capital increased to Rs. 20,92,32,408, comprising 20,92,32,408 equity shares of Rs. 1/- each.
- H1 FY27 Revenue Growth: Reported H1 revenue of Rs. 566.6 crore, reflecting a 26% year-on-year increase.
- Q2 FY27 Performance: Q2 revenue recorded at Rs. 309.1 crore, marking a 25% year-on-year growth.

- [Intimation of allotment of Bonus equity shares |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CONCORD_05112026180857_Concord_Intimation_of_Allotment.pdf)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Concord Biotech Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/CONCORD_03112026153540_Q2FY27_Earnings_Call_Transcript.pdf)
- [Concord Biotech Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21008_WebXMLFile_20261103_180508154.xml)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)

### Fundamentals

Concord Biotech’s operating trajectory shows a clear recovery in the June 2026 quarter (Q2 FY2026-27), with revenue rising 20% sequentially to ₹309 crore and net profit increasing 21% to ₹69.6 crore. This follows a significant contraction in the prior year, where full-year sales fell from ₹1,200 crore (Mar 2025) to ₹1,055 crore (Mar 2026). Despite this recent rebound, earnings quality remains under pressure; the Compounded Profit Growth over three years is just 1%, and TTM profit growth is -8%. The balance sheet reflects ongoing expansion, with Capital Work-in-Progress (CWIP) rising to ₹112 crore by Sep 2026 and total assets growing to ₹2,327 crore. However, working capital efficiency has deteriorated sharply, with the Cash Conversion Cycle widening to 492 days in Mar 2026, driven primarily by Inventory Days jumping to 483 days. While borrowings are low at ₹1 crore, cash reserves dropped to ₹7.52 crore as of Sep 2026, suggesting liquidity management is becoming tighter amid higher inventory levels.

- Sequential Recovery: Q2 FY2026-27 revenue grew 20% to ₹309 crore and net profit rose 21% to ₹69.6 crore, reversing the previous year's decline.
- Earnings Quality Gap: Long-term profitability remains weak with 3-year compounded profit growth at 1% and TTM profit growth at -8%, despite recent quarterly improvements.
- Working Capital Strain: The Cash Conversion Cycle widened significantly to 492 days (Mar 2026), driven by Inventory Days surging to 483 days, indicating slower stock turnover.
- Liquidity Watch: Cash and cash equivalents fell to ₹7.52 crore as of Sep 2026, while CWIP increased to ₹112 crore, highlighting potential funding needs for ongoing capex.

### Bear Case

Concord Biotech faces a deteriorating technical setup and significant price volatility, underscoring near-term downside risks. As of November 6, 2026, the stock trades at ₹628.0, reflecting a year-to-date decline of -6.0% and a substantial current drawdown of -46.5% from its peak. The daily trend is bearish, with the Supertrend indicator signaling downward pressure and moving averages (20-day and 50-day) sloping negatively (-12.14% and -15.19% respectively). Monthly trends reinforce this caution, showing a strong bearish Supertrend direction and an ADX of 46.4, indicating a robust downtrend. While the weekly timeframe shows a bullish Supertrend, the immediate daily and monthly momentum remains weak, with resistance levels clustered closely above the current price (₹628.62 to ₹656.47) and support testing lower at ₹606.25. High annualized volatility of +45.4% further amplifies risk for investors holding positions during this consolidation phase.

- Current drawdown stands at -46.5%, with YTD returns at -6.0% and 1-month returns at -8.2%, indicating sustained underperformance.
- Daily technicals are bearish: Supertrend is down, and both 20-day (-12.14%) and 50-day (-15.19%) moving average slopes are negative.
- Monthly trend confirms weakness with a bearish Supertrend and high ADX (46.4), suggesting persistent downward momentum.
- High annualized volatility (+45.4%) and ATR percent (11.19%) signal elevated price instability and risk.

- [Multibagger Jhunjhunwala stock is showing 50% fall today; here's why](https://www.businesstoday.in/markets/stocks/story/multibagger-jhunjhunwala-stock-is-showing-50-fall-today-heres-why-565560-2026-11-04)
- [Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanza](https://economictimes.indiatimes.com/markets/stocks/news/bonus-issue-alert-last-day-to-buy-this-rakesh-jhunjhunwala-backed-smallcap-pharma-stock-for-11-bonus-bonanza/articleshow/135479214.cms)
- [Dividend, bonus issue: Last chance to buy today — Godrej Consumer, Coal India, Asian Paints and others](https://www.livemint.com/market/stock-market-news/dividend-bonus-issue-last-chance-to-buy-today-godrej-consumer-coal-india-asian-paints-and-others-11793640245000.html)
- [Bonus share: Just single issue with record date this week: Pharma firm's free shares with 68% returns since IPO; ratio](https://www.livemint.com/market/stock-market-news/bonus-share-just-single-issue-with-record-date-this-week-pharma-firms-free-shares-with-68-returns-since-ipo-ratio-11793517001201.html)
- [Intimation of allotment of Bonus equity shares |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CONCORD_05112026180857_Concord_Intimation_of_Allotment.pdf)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Concord Biotech Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/CONCORD_03112026153540_Q2FY27_Earnings_Call_Transcript.pdf)
- [Concord Biotech Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21008_WebXMLFile_20261103_180508154.xml)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)

### FAQs

**Why did Concord Biotech's share price fall nearly 50% on November 4, 2026?**

The sharp decline was due to the stock going ex-bonus following a 1:1 bonus issue. This corporate action doubled the number of shares while proportionally adjusting the share price, leaving the total investment value unchanged. The apparent drop occurred because some trading applications displayed unadjusted previous closing prices rather than the new post-split valuation.

**What are the key details and timeline of the recent bonus issue?**

Concord Biotech issued 10.46 crore fully paid-up bonus equity shares in a 1:1 ratio based on the record date of November 4, 2026. Eligible investors must have held shares by November 3. The allotment was intimated on November 5, increasing the company’s paid-up capital to ₹20,92,32,408 across 20,92,32,408 equity shares of Re 1 each.

**How has the stock performed recently, and what is its current technical trend?**

As of November 6, 2026, the stock closed at ₹628.00, reflecting a -6.0% year-to-date return and an -11.0% one-year return. Technical indicators show a bearish daily supertrend with an ADX of 22.45, suggesting weak momentum. The stock is currently trading near immediate resistance at ₹628.62 and support at ₹626.47.

- [Multibagger Jhunjhunwala stock is showing 50% fall today; here's why](https://www.businesstoday.in/markets/stocks/story/multibagger-jhunjhunwala-stock-is-showing-50-fall-today-heres-why-565560-2026-11-04)
- [Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanza](https://economictimes.indiatimes.com/markets/stocks/news/bonus-issue-alert-last-day-to-buy-this-rakesh-jhunjhunwala-backed-smallcap-pharma-stock-for-11-bonus-bonanza/articleshow/135479214.cms)
- [Dividend, bonus issue: Last chance to buy today — Godrej Consumer, Coal India, Asian Paints and others](https://www.livemint.com/market/stock-market-news/dividend-bonus-issue-last-chance-to-buy-today-godrej-consumer-coal-india-asian-paints-and-others-11793640245000.html)
- [Bonus share: Just single issue with record date this week: Pharma firm's free shares with 68% returns since IPO; ratio](https://www.livemint.com/market/stock-market-news/bonus-share-just-single-issue-with-record-date-this-week-pharma-firms-free-shares-with-68-returns-since-ipo-ratio-11793517001201.html)
- [Intimation of allotment of Bonus equity shares |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CONCORD_05112026180857_Concord_Intimation_of_Allotment.pdf)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Concord Biotech Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/CONCORD_03112026153540_Q2FY27_Earnings_Call_Transcript.pdf)
- [Concord Biotech Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21008_WebXMLFile_20261103_180508154.xml)
- [SERIES:EQ |PURPOSE:BONUS 1:1 |FACE VALUE:1 |RECORD DATE:04-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Moderate Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹670.23
- Risk regime: Higher Price Risk

### Support levels
- 628.625
- 606.25
- 577.15

### Resistance levels
- 697.8
- 726.35
- 803.5

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -6.64% |
| return_10 | +2.17% |
| return_1m | -8.24% |
| return_1y | -11.01% |
| return_20 | -5.62% |
| return_3m | -8.63% |
| return_5 | +0.83% |
| return_6m | +2.78% |
| return_since_start | -41.55% |
| return_ytd | -6.01% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -56.74% |
| annualized_volatility | +45.37% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Concord Biotech Limited Q2 FY2026-27: Revenue rises 20% sequentially

Concord Biotech’s consolidated revenue from operations rose 20% sequentially to ₹309.1 crore in Q2 FY2026-27, while profit before tax increased 25% to ₹96.1 crore. Profit for the period was ₹69.6 crore and basic EPS was ₹6.65; revenue and profit were also up 25% and 10%, respectively, year on year.

## Revenue and income

Revenue from operations increased from ₹257.5 crore in Q1 FY2026-27 to ₹309.1 crore in Q2. Total income rose 18% sequentially to ₹319.2 crore, including other income of ₹10.2 crore. Compared with Q2 FY2025-26, revenue was up 25% and total income increased 23%.

Revenue recovered from ₹257.5 crore in Q1 FY2026-27 after reaching ₹326.1 crore in Q4 FY2025-26. Q2 FY2026-27 revenue was the second-highest in the five-quarter series provided.

## Expenses and profitability

Total expenses increased 15% sequentially to ₹223.1 crore, below the 20% increase in revenue. Q2 expenses included ₹63.7 crore for materials consumed, ₹16.2 crore for purchases of stock in trade and ₹52.3 crore in employee benefit expense. Profit before tax rose 25% from ₹77.1 crore in Q1 FY2026-27 to ₹96.1 crore. Year on year, expenses grew 26% and profit before tax rose 15%.

Profit for the period increased 21% sequentially to ₹69.6 crore, from ₹57.7 crore in Q1 FY2026-27, and was 10% above Q2 FY2025-26. Profit attributable to owners of the parent was ₹70.7 crore; a ₹1.1 crore loss was attributable to non-controlling interests. Finance costs were ₹3.34 lakh, compared with ₹3.64 lakh in Q1 FY2026-27.

## Tax and per-share earnings

Tax expense was ₹25.9 crore, up 25% sequentially, broadly in line with the increase in pre-tax profit. Basic and diluted EPS were both ₹6.65 in Q2 FY2026-27, compared with ₹5.52 in Q1 FY2026-27 and ₹6.03 in Q2 FY2025-26. EPS in Q4 FY2025-26 was ₹8.46.

## Comprehensive income

Other comprehensive income was a loss of ₹8.6 crore in Q2 FY2026-27, compared with a gain of ₹17.1 crore in Q1. Total comprehensive income consequently declined 18% sequentially to ₹61.0 crore, despite the increase in profit for the period.

## Liquidity and balance sheet

At 30 September 2026, cash and cash equivalents were ₹7.5 crore, down from ₹12.2 crore at 31 March 2026. Current investments increased over the same period from ₹402.1 crore to ₹438.1 crore.

Total assets stood at ₹2,327.0 crore at 30 September 2026, up from ₹2,234.7 crore at 31 March 2026. Equity increased from ₹2,015.1 crore to ₹2,071.9 crore, while liabilities rose from ₹219.6 crore to ₹255.1 crore.

Inventories increased to ₹397.8 crore from ₹326.4 crore at 31 March 2026, while trade receivables declined to ₹412.5 crore from ₹460.2 crore. Trade payables rose to ₹112.1 crore from ₹101.9 crore. Capital work in progress increased to ₹111.6 crore from ₹78.2 crore, while property, plant and equipment declined to ₹759.6 crore from ₹785.7 crore.

## Key Takeaway

Q2 FY2026-27 brought a strong sequential rebound in revenue, with profit before tax growing faster than sales and net profit also higher year on year. The main contrasts were lower comprehensive income following an OCI loss and a larger inventory balance at period-end; cash balances declined while current investments increased.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +44.09%
- FII holding: +7.28%
- DII holding: +10.95%
- Mutual fund holding: +5.84%
- Retail holding: +7.61%
- Promoter pledged: +0.00%

### Major reported shareholders

- Sudhir Kumar Vaid — +28.84%
- Manju Vaid — +9.55%
- Aryavir Jhunjhunwala Discretionary Trust — +8.03% (Trusts)
- Aryaman Jhunjhunwala Discretionary Trust — +8.03% (Trusts)
- Nishtha Jhunjhunwala Discretionary Trust — +8.03% (Trusts)
- Sudman Consultants Llp — +4.54% (Bodies Corporate)
- Dsp Small Cap Fund — +3.21%
- Government Pension Fund Global — +2.95%
- Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund — +2.68%
- Axis Max Life Insurance Limited Ac Reversionary Bonus Participating Equity — +1.33%

## Official filings

- 2026-11-05 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_05112026180857_Concord_Intimation_of_Allotment.pdf)
- 2026-11-04 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-04 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-04 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-03 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-03 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-03 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-03 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_03112026153540_Q2FY27_Earnings_Call_Transcript.pdf)
- 2026-11-03 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21008_WebXMLFile_20261103_180508154.xml)
- 2026-11-02 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-02 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-02 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-10-30 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-10-30 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-10-30 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-10-29 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-10-29 — Corporate Action Notice: Concord Biotech Limited - Ex-Date: 04-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-10-28 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_28102026150258_F_Press_release_Intimation.pdf)
- 2026-10-28 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21008_WebXMLFile_20261028_151416612.xml)
- 2026-10-28 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_28102026150953_Intimation_to_Stock_Exchanges.pdf)
- 2026-10-28 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_28102026184346_Q2FY27EarningCallOutcome.pdf)
- 2026-10-28 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21008_WebXMLFile_20261028_184929048.xml)
- 2026-10-27 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_27102026190620_Concord_Outcome_of_BM.pdf)
- 2026-10-27 — Financial Results Filing: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747161_27102026071147_WEB.xml)
- 2026-10-27 — Financial Results Filing: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747159_27102026071141_WEB.xml)

## News and market events

- 2026-11-07 — The Hindu: **Concord Biotech: Recovering business momentum and new ventures support growth** — Concord Biotech is reporting a recovery in business momentum with 26% year-on-year revenue growth in H1FY27, driven by its fermentation-based API base and new injectables and CDMO ventures. Although profitability margins have temporarily declined due to costs associated with these new expansions and recent market headwinds, the company aims to bridge this deficit as utilization of its new entities increases over the next two to three years. The firm maintains a strong financial position with zero debt and significant cash reserves, supporting its -term growth outlook. — [Source](https://www.thehindubusinessline.com/portfolio/stock-fundamental-analysis-india/concord-biotech-recovering-business-momentum-and-new-ventures-support-growth/article71670378.ece)
- 2026-11-04 — BUSINESSTODAY: **Multibagger Jhunjhunwala stock is showing 50% fall today; here's why** — Shares of Jhunjhunwala-backed Concord Biotech appeared to fall nearly 50% on November 4, 2026, as the stock went ex-bonus following a 1:1 bonus issue approved by the board. This corporate action adjusted the share price proportionally while doubling the number of shares held by eligible investors, leaving the total investment value unchanged. The apparent sharp decline was largely due to some trading apps displaying unadjusted previous closing prices rather than the new post-split valuation. — [Source](https://www.businesstoday.in/markets/stocks/story/multibagger-jhunjhunwala-stock-is-showing-50-fall-today-heres-why-565560-2026-11-04)
- 2026-11-03 — Economic Times: **Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanza** — Concord Biotech, a smallcap pharma firm backed by the late Rakesh Jhunjhunwala, has set November 4 as the record date for its 1:1 bonus issue, making the preceding trading day the last opportunity for investors to purchase shares and qualify for the allotment. The company announced in September that it would issue 10.46 crore bonus shares with a face value of Re 1 each by capitalising its share premium account, with allotments scheduled for November 5. This corporate action comes as the stock has declined nearly 13% in 2026 and over 15% in the past month, while Jhunjhunwala’s associates held a — [Source](https://economictimes.indiatimes.com/markets/stocks/news/bonus-issue-alert-last-day-to-buy-this-rakesh-jhunjhunwala-backed-smallcap-pharma-stock-for-11-bonus-bonanza/articleshow/135479214.cms)
- 2026-11-02 — Mint: **Dividend, bonus issue: Last chance to buy today — Godrej Consumer, Coal India, Asian Paints and others** — Godrej Consumer Products, Privi Speciality Chemicals, Coal India, Symphony, and Asian Paints have set November 4, 2026, as the record date for their FY27 interim dividends, while Concord Biotech has designated the same date for its approved 1:1 bonus share issue. These corporate actions require investors to hold shares in their demat accounts before the cutoff to qualify for payouts or additional equity. The article highlights these deadlines alongside recent quarterly financial results from several of the listed companies. — [Source](https://www.livemint.com/market/stock-market-news/dividend-bonus-issue-last-chance-to-buy-today-godrej-consumer-coal-india-asian-paints-and-others-11793640245000.html)
- 2026-11-01 — Mint: **Bonus share: Just single issue with record date this week: Pharma firm's free shares with 68% returns since IPO; ratio** — Concord Biotech Limited has set November 4 as the record date for its 1:1 bonus share issue, requiring investors to hold shares by November 3 to qualify. This is reported as the only bonus issue record date scheduled for the coming week on the BSE. — [Source](https://www.livemint.com/market/stock-market-news/bonus-share-just-single-issue-with-record-date-this-week-pharma-firms-free-shares-with-68-returns-since-ipo-ratio-11793517001201.html)
- 2026-10-27 — The Hindu: **Flat opening seen amidst positive Asian markets** — Gift Nifty is ruling at 22,760 with respect to Nifty futures closing of 22,774 on the NSE. Key results will anchor today’s movement — [Source](https://www.thehindubusinessline.com/markets/flat-opening-seen-amidst-positive-asian-markets/article71629598.ece)
- 2026-09-24 — MONEYCONTROL: **Buzzing Stocks: Max Estates gains 6% on JDA; Concord Biotech rises 4% after bonus share approval** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-max-estates-up-6-on-joint-development-agreement-concord-biotech-rises-4-on-bonus-shares-approval-14036932.html)
- 2026-09-24 — BUSINESS: **Stock Alert: Avantel, IOL Chem, Concord Biotech,ESAF SFB, NSE** — Kaynes Tech, LIC Housing Finance, Manappuram Finance, SAIL barred from F&O trading on 24 September 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-avantel-iol-chem-concord-biotech-esaf-sfb-nse-126092400179_1.html)
- 2026-09-24 — BUSINESSTODAY: **GIFT Nifty down 190 pts; NSE, Sedemac, Nephrocare, Ola Electric, telcos among top stocks in focus** — GIFT Nifty, GIFT Nifty cues today, GIFT Nifty Signals today, Stocks in news, Stocks in buzz, Stocks to buy, NSE, National Stock Exchange of India, Sedemac Mechatronics, Nephrocare Health Services, Ola Electric Mobility, Bharat Electronics, Max Estates, GHCL telcos, insurance companies, Vodafone Idea, Reliance Industries, Bharti Airtel, Exide Industries, Concord Biotech, Rainbow Children's Medicare, Avantel, GCHL, Zuari Industries, Pyramid Technoplast — [Source](https://www.businesstoday.in/markets/trending-stocks/story/gift-nifty-down-190-pts-nse-sedemac-nephrocare-ola-electric-telcos-among-top-stocks-in-focus-557423-2026-09-24)
- 2026-09-23 — CNBC-TV18: **Stocks to Watch for September 24: NTPC, Bharat Dynamics, Exide Industries, Concord Biotech and more** — From NTPC paying a final dividend of ₹3,393.83 crore for FY26 to the Ministry of Defence signing an ₹810.79-crore contract with Bharat Dynamics Ltd (BDL) for 160 Satellite Smart Anti-Airfield Weapons and associated equipment for the Indian Air Force, here are the stocks to track ahead of Thursday’s trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-september-24-ntpc-bharat-dynamics-exide-industries-concord-biotech-and-more-19996826.htm)
- 2026-09-23 — CNBC-TV18: **Concord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each held** — Concord Biotech has approved a 1:1 bonus share issue, allowing shareholders to receive one additional share for every share held. The company will issue 10.46 crore bonus shares, doubling its paid-up capital to ₹20.92 crore. — [Source](https://www.cnbctv18.com/market/concord-biotech-announces-11-bonus-share-issue-shareholders-to-get-one-free-share-for-each-held-19996820.htm)
- 2026-09-23 — Mint: **Concord Biotech 1:1 bonus issue: Jhunjhunwala family-backed pharma stock gains 50% in 6 months, check record date detail** — Concord Biotech Limited announced its first-ever 1:1 bonus issue, approved by its board on September 23. The stock rose nearly 2%, reflecting investor interest — [Source](https://www.livemint.com/market/stock-market-news/concord-biotech-1-1-bonus-issue-jhunjhunwala-family-backed-pharma-stock-gains-50-in-6-months-check-record-date-detail-11790165743583.html)
- 2026-09-21 — Mint: **Concord Biotech bonus issue sparks rally! Pharma stock jumps 6% on maiden share reward - Top things to know** — Concord Biotech shares surged nearly 6% after announcing a bonus issue. The board will meet on September 23, 2026, to discuss issuing bonus shares to existing shareholders. — [Source](https://www.livemint.com/market/stock-market-news/concord-biotech-bonus-issue-sparks-rally-pharma-stock-jumps-6-on-maiden-share-reward-top-things-to-know-11789984107486.html)
- 2026-09-18 — BUSINESS: **Nifty settles above 23,300 as Moody's GDP upgrade, easing oil support sentiment** — The key equity benchmarks ended mixed on Friday, as easing crude oil prices and softer global bond yields supported investor sentiment. Market sentiment was also aided by Moody's upward revision of India's FY27 GDP growth forecast to 7% from 6%, citing stronger-than-expected domestic activity and the resilience of the economy amid the ongoing conflict in West Asia. However, Moody's flagged elevated energy prices and El Ni-related food price pressures as risks to inflation, consumption and growth. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-settles-above-23-300-as-moody-s-gdp-upgrade-easing-oil-support-sentiment-126091800939_1.html)
- 2026-09-18 — BUSINESS: **Indices end sideways; metal shares shine for 3rd day** — In the primary market, the NSE IPO was fully subscribed, while investors continued to track subscription trends in other ongoing issues and monitor the listing performance of recently listed companies. — [Source](https://www.business-standard.com/markets/capital-market-news/indices-end-sideways-metal-shares-shine-for-3rd-day-126091800788_1.html)
- 2026-09-18 — BUSINESS: **Benchmarks trade near the day's high; European markets trade lower** — The benchmark indices traded near the day's high in afternoon trade, supported by easing crude oil prices and softer global bond yields. Market sentiment also received a boost after Moodys raised its India FY27 GDP growth forecast to 7%, citing the resilience of the domestic economy despite ongoing geopolitical tensions in West Asia. The Nifty regained the 23,300 mark. — [Source](https://www.business-standard.com/markets/capital-market-news/benchmarks-trade-near-the-day-s-high-european-markets-trade-lower-126091800572_1.html)
- 2026-09-18 — BUSINESS: **Concord Biotech's Valthera unit completes US FDA audit with one procedural observation** — Concord Biotech said that the U.S. Food and Drug Administration (US FDA) had successfully concluded the inspection of the company's Valthera Formulation Facility, with one minor procedural observation. — [Source](https://www.business-standard.com/markets/capital-market-news/concord-biotech-s-valthera-unit-completes-us-fda-audit-with-one-procedural-observation-126091800453_1.html)
- 2026-09-14 — Economic Times: **Samir Arora-backed Helios Mid Cap Fund exits Dixon Technologies, 2 others; adds 7 stocks** — Helios Mid Cap Fund, backed by Samir Arora, exited Dixon Technologies, Aadhar Housing Finance and Black Box in August. The fund added eight stocks, including Coforge and Lalithaa Jewellery, while increasing exposure to 15 stocks and holding 72 stocks across 23 sectors. — [Source](https://economictimes.indiatimes.com/mf/analysis/samir-arora-backed-helios-mid-cap-fund-exits-dixon-technologies-2-others-adds-7-stocks/articleshow/134231976.cms)
- 2026-09-01 — CNBC-TV18: **Symbiotec Pharmalab shares to list today; GMP signals 19% premium over IPO price** — If grey market trends are anything to go by, the stock could make a strong debut with a premium of around 19% over its issue price. The grey market premium (GMP) currently stands at ₹185, indicating an estimated listing price of around ₹1,173 per share, compared with the IPO price of ₹988. — [Source](https://www.cnbctv18.com/market/symbiotec-pharmalab-share-price-ipo-listing-today-premium-discount-gmp-signals-issue-price-nse-bse-19980955.htm)
- 2026-08-24 — The Hindu: **Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon** — The employee reservation portion led with 1.19 times subscription; Retail Individual Investors subscription at 0.82 times, NII category is at 0.86 times. QIB remained the weakest segment at 0.35 times — [Source](https://www.thehindubusinessline.com/markets/symbiotec-pharmalab-ipo-sees-subscription-at-070x-by-mid-afternoon/article71384017.ece)
- 2026-08-24 — Economic Times: **Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?** — Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity. — [Source](https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms)
- 2026-08-18 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Concord Biotech (₹1,513.40) – BUY** — Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Concord Biotech. The stock began the week on a strong note, rising 4.2 per cent on Monday — [Source](https://www.thehindubusinessline.com/markets/stock-market-live-sensex-nifty50-today-live-updates-today-18th-august-2026/article71358725.ece)
- 2026-08-17 — Economic Times: **Market Trading Guide: Hindustan Copper among 2 stock recommendations for Tuesday** — Analysts recommend Hindustan Copper and Concord Biotech after both stocks broke key resistance levels with strong price action, volume and bullish momentum. Despite energy-led cost pressures, stronger Q1FY27 earnings and pricing actions could support upgrades, though margin risks remain from higher-cost inventory. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/market-trading-guide-hindustan-copper-among-2-stock-recommendations-for-tuesday/articleshow/133300251.cms)
- 2026-08-10 — CNBC-TV18: **Top 8 Nifty 500 movers: From Hitachi Energy to Kaynes Tech, here are the biggest gainers and losers at opening** — The Nifty 500 saw active trading at market open today, with power, diagnostics and travel-tech names leading gains while electronics manufacturing and fashion retail slipped.Here's a look at the stocks that stood out as today's biggest movers on the index this morning. — [Source](https://www.cnbctv18.com/photos/market/nifty-500-top-gainers-losers-market-open-hitachi-energy-vijaya-diagnostics-kaynes-ola-electric-19965194.htm)
- 2026-08-10 — MONEYCONTROL: **Trade Spotlight: How should you trade Uno Minda, Glenmark Pharma, APL Apollo Tubes, Grasim Industries, TCS, and others on August 10?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Uno Minda,Glenmark Pharmaceuticals,APL Apollo Tubes,BLS International Services,Concord Biotech,Grasim Industries,Vedanta,Tata Consultancy Services — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-uno-minda-glenmark-pharma-apl-apollo-tubes-grasim-industries-tcs-and-others-on-august-10-13999267.html)

## Business profile

**Strategic vision:** Biopharmaceutical company developing and manufacturing APIs and formulations.

### Business segments
- **Active Pharmaceutical Ingredients (API):** The company manufactures niche and reliable APIs using fermentation and semi-synthetic methods, maintaining high-quality benchmarks. The API facility is dedicated to producing high-quality APIs.
- **Formulations:** Concord Biotech develops and manufactures niche formulations aimed at improving health outcomes for patients globally. This segment includes both global formulations and branded generic products for the Indian market.
- **Contract Development & Manufacturing Services (CDMO):** The company provides comprehensive Contract Development & Manufacturing Services, supported by technical expertise and adhering to global regulatory approvals.

### Competitive strengths
- Over two and a half decades of experience in the biopharmaceutical industry.
- Leveraging advanced fermentation and semi-synthetic technologies.
- State-of-the-art manufacturing facilities meeting stringent international quality standards.

## Related stocks

- [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23%
- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56%
- [Eris Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/eris) — +0.58%
- [Granules India Limited (Healthcare)](https://faxioms.com/stocks/granules) — +0.12%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/concordbio
Markdown representation: https://faxioms.com/stocks/concordbio?render=md